Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion
2025-10-20 07:15:34 ET
The last time I wrote about Achieve Life Sciences (ACHV), it was with respect to a Seeking Alpha article entitled " Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement ". At that time, I had rated it as a "Buy" rating, and I'm going to maintain that rating I set beforehand. There are two reasons why I believe this should be the case. The first reason is that there was an update relating to the use of its drug cytisinicline for the treatment of nicotine dependence for smoking cessation. In particular, I'm happy to report that the FDA not only accepted the New Drug Application [NDA] of this drug for the treatment of smoking cessation for these adult patients but also set a Prescription Drug User Fee Act [PDUFA] date of June 20, 2026, for it....
Read the full article on Seeking Alpha
For further details see:
Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion
NASDAQ: ACHV
ACHV Trading
4.47% G/L:
$5.37 Last:
453,265 Volume:
$5.35 Open:
